spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Erbitux 

 HSMN NewsFeed - 24 Oct 2024
Pillar Biosciences Receives CPT(R) Code for FDA Approved oncoReveal(TM) CDx Pan-Cancer Solid tumor IVD Kit
Diagnostics Oncology Reimbursement
 HSMN NewsFeed - 2 Jun 2021
MorphImmune, Inc. Appoints Ronald Martell as President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Apr 2019
OncoSec Appoints Industry Veteran Margaret R. Dalesandro, Ph.D., to its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Sep 2018
Halozyme Names Benjamin Hickey As Chief Commercial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 24 May 2018
Curis Expands Senior Management Expertise with Appointment of Robert Martell, M.D., Ph.D., as Head of Research and Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 3 Jan 2018
Agenus Announces Key Leadership to Advance Combination Trials For Planned BLA Filings
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 Jan 2017
Verastem Announces Executive Leadership Appointments and Changes
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 30 Nov 2016
Celldex Therapeutics Completes Acquisition of Kolltan Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 6 Apr 2016
Merck and Sysmex Inostics Receive CE Mark Approval for Liquid Biopsy test for Colorectal Cancer Patients
Diagnostics Oncology Regulatory
 HSMN NewsFeed - 20 Jan 2016
Immunotherapy Company PDS Biotechnology Strengthens Senior Management Team, Adds Two Drug Development Executives
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 May 2015
Roche Receives FDA Approval for cobas(R) KRAS Mutation Test
Diagnostics Oncology FDA
 HSMN NewsFeed - 7 Jan 2015
AVEO Announces Executive Transition and Corporate Restructuring
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Sep 2014
Dimension Therapeutics Names Annalisa Jenkins as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Mar 2014
Tocagen Names Jamey Skillings, M.D., Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 23 Dec 2013
European Commission Approves Update of Erbitux Metastatic Colorectal Cancer Labeling to Patients With RAS Wild-Type Tumors
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 28 Oct 2013
Advaxis Appoints Gregory T. Mayes as Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 May 2013
Third Rock Ventures Expands and Strengthens Team
Biopharmaceuticals Devices Venture Capital Personnel
 HSMN NewsFeed - 3 Jan 2013
Advaxis Appoints Daniel J. O'Connor to Senior Vice President, Chief Legal and Business Development Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Oct 2012
Principia Biopharma Secures $12.5M Second Tranche In Series A Financing, Expands Senior Management Team
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 12 Mar 2012
Synta Announces Appointment of Dvorit Samid, Ph.D., as Vice President, Medical Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Feb 2012
Threshold Pharmaceuticals and Merck KGaA Announce Global Agreement to Co-Develop and Commercialize Phase 3 Hypoxia-Targeted Drug TH-302
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Feb 2012
Dendreon Announces CEO and Chairman Succession Plan
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jan 2012
NeurogesX Appoints Ronald Martell President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Nov 2011
Curis Announces Appointment of Maurizio Voi, M.D. as Chief Medical and Chief Development Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Sep 2011
Curis, Inc. Announces Appointment of Robert Martell, M.D., Ph.D. to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Jul 2011
ZIOPHARM Oncology Appoints Hagop Youssoufian, M.Sc., M.D., as Executive Vice President and Chief Medical Officer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Jun 2011
Spectrum Pharmaceuticals Announces Promotions of Steven M. Fruchtman, MD, to Chief Medical Officer, Head of Medical & Regulatory Affairs, and Nozar Azarnia, PhD, to Head of Biostatistics and Data Management
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Apr 2011
Arno Therapeutics Announces the Appointment of Mr. Glenn Mattes as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Feb 2011
Constellation Pharmaceuticals Expands Leadership Team with Drug Development Industry Veterans
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Dec 2010
InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet (Pirfenidone) in Europe
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Sep 2010
AVEO Pharmaceuticals, Inc. Appoints Michael P. Bailey to the Newly Created Position of Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Sep 2010
Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Apr 2010
Aeterna Zentaris Announces Initiation of Phase 3 Registration Trial with Perifosine in Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Apr 2010
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Mar 2010
Merck Serono: Erbitux Granted Extended Use in Japan for 1st-Line Treatment of mCRC Patients with KRAS Wild-Type Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Jan 2010
Medco to Advance Cancer Care with Personalized and Specialized Treatment for Oncology Patients
Biopharmaceuticals Personalized Medicine Oncology
 HSMN NewsFeed - 23 Sep 2009
Data Presented from Two Phase 3 ERBITUX(R) Studies in First-Line Metastatic Colorectal Cancer Patients at Joint 15th European Cancer Organisation and 34th European Society for Medical Oncology Multidisciplinary Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Jul 2009
ImClone Systems and Bristol-Myers Squibb Announce Revisions to ERBITUX(R) (cetuximab) U.S. Product Labeling for Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Jun 2009
Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients
Diagnostics Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2009
UK's NICE Recommends Use of Erbitux for Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 May 2009
Merck Serono Initiates SETTLE, the Second Phase III Clinical Trial of Safinamide in Advanced Parkinson's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 5 May 2009
Merck Serono Launches Glucophage Powder in First European Countries
Biopharmaceuticals Endocrinology Regulatory
 HSMN NewsFeed - 21 Apr 2009
Merck Serono Launches Kuvan(R) in Europe
Biopharmaceuticals
 HSMN NewsFeed - 6 Apr 2009
ARIAD Appoints Former Bristol-Myers Squibb Senior Executive as New Independent Member of Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Mar 2009
Merck Serono Launches Strategic Venture Capital Fund
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 2 Mar 2009
ImClone Systems and Bristol-Myers Squibb Update Status of First-Line Squamous Cell Carcinoma of the Head and Neck Supplemental Biologics Application for ERBITUX(R) in U.S.
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Feb 2009
Merck Serono and Ambrx Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
Biopharmaceuticals Neurology
 HSMN NewsFeed - 19 Feb 2009
European Medicines Agency Recommends Suspension of Marketing Authorization for Raptiva(R)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 3 Feb 2009
Merck Serono's Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinson's Disease in a Phase III Pivotal Trial
Biopharmaceuticals Neurology
 HSMN NewsFeed - 23 Jan 2009
ImClone Systems and Bristol-Myers Squibb Update the Status of Non-Small Cell Lung Cancer Supplemental Biologics Application Submission for ERBITUX(R)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Jan 2009
Merck Serono's Oral Investigational Treatment Cladribine Tablets for Multiple Sclerosis Significantly Reduced Relapse Rate in Two-Year Phase III Pivotal Trial
Biopharmaceuticals Neurology
 HSMN NewsFeed - 13 Jan 2009
Merck Serono and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 22 Dec 2008
Myriad Genetics Launches Sixth Personalized Medicine Product, Prezeon -- to Reveal PTEN Status
Diagnostics Oncology
 HSMN NewsFeed - 9 Dec 2008
Merck Serono's Kuvan(R) Receives Marketing Authorization in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 8 Dec 2008
ERBITUX® Supplemental Biologics License Application for Advanced Non-Small Cell Lung Cancer Submitted to U.S. Food and Drug Administration
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Dec 2008
Avila Therapeutics Appoints Daniel S. Lynch as Executive Chairman
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Nov 2008
Lilly Completes Acquisition of ImClone Systems
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 24 Nov 2008
NCCN Receives $1.5 Million Grant to Research Targeted Therapy in Bladder Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Nov 2008
NCCN Updates Guidelines for Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Oct 2008
ImClone Announces ERBITUX(R) Commercial Launch in Canada for Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Oct 2008
Study Published in New England Journal of Medicine Shows K-ras Gene Mutation Status May Affect Response to ERBITUX(R) Treatment
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Oct 2008
ImClone Announces Merger Agreement with Eli Lilly at $70 Per Share
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 6 Oct 2008
Lilly to Acquire ImClone Systems in $6.5 Billion Transaction
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 26 Sep 2008
Merck Serono's Kuvan(R) Recommended for European Approval
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 Sep 2008
Results From IMPROVE Study Show Therapeutic Effect of New Formulation of Rebif(R) at 16 Weeks in Patients With Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 19 Sep 2008
ERBITUX(R) Now Available in Japan for Use in Treating Patients with Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Sep 2008
ImClone Provides Update on Pivotal Phase 3 CRYSTAL Study in First-Line Metastatic Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Sep 2008
New Data Confirms Avastin (R) as the Only Biologic to Demonstrate Overall Survival When Used First-Line in Metastatic Colorectal Cancer Patients With K-RAS (Wild-Type) Gene Status
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Sep 2008
Bristol-Myers Squibb Submits Letter to ImClone Board of Directors
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 3 Sep 2008
ImClone Submits Supplemental Biologics License Application for ERBITUX(R) in First-Line Head and Neck Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Aug 2008
Monoclonal Antibody Sales to Almost Double in Coming Years
Biopharmaceuticals
 HSMN NewsFeed - 29 Aug 2008
ERBITUX(R) Phase 3 BMS-099 Lung Cancer Study Secondary Endpoint Update: Overall Survival Results Announced
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Aug 2008
ImClone Systems Issues Statement
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 31 Jul 2008
Bristol-Myers Squibb Proposes to Acquire ImClone Systems for $60.00 Per Share in Cash
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 16 Jul 2008
ERBITUX(R) (Cetuximab) Receives Approval in Japan for Use in Advanced Colorectal Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Jul 2008
Synta Pharmaceuticals Names Michael P. Bailey Senior Vice President and Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Jul 2008
ImClone Announces Changes in Commercial Organization Leadership
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jul 2008
Clarient Launches New Colorectal Cancer Test
Diagnostics Oncology
 HSMN NewsFeed - 10 Jun 2008
Merck Serono Strengthens its Prescription Medicines Portfolio in Latin America
Biopharmaceuticals Distribution
 HSMN NewsFeed - 10 Jun 2008
Merck Serono's Rebif(R) Celebrates 10th Anniversary
BIopharmaceuticals Neurology
 HSMN NewsFeed - 5 Jun 2008
Merck Serono Announces Initiation of Second Phase II/III Clinical Study of Atacicept in Lupus
Biopharmaceuticals
 HSMN NewsFeed - 2 Jun 2008
ImClone Appoints Dr. Bernhard Ehmer Senior Vice President and Managing Director, International Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jun 2008
New Analyses of Pivotal Phase 3 Study of ERBITUX(R) Demonstrate Enhanced Efficacy in First-Line Metastatic Colorectal Cancer Patients with Wild-Type K-Ras Biomarker
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
ERBITUX(R) (Cetuximab) Data Demonstrate Improved Overall Survival in First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 May 2008
ERBITUX(R) (cetuximab) Data Demonstrate Improvements in Response Rate and Progression-Free Survival in Wild Type K-Ras Metastatic Colorectal Cancer Patients in First-Line Setting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 May 2008
Unique Three-Year Data Demonstrating Long-Term Efficacy and Safety of Raptiva(R) in the Treatment of Psoriasis Published in the British Journal of Dermatology
Biopharmaceuticals
 HSMN NewsFeed - 16 Apr 2008
Merck Announces Planned Investment of $50 Million in Research Center in the US
Biopharmaceuticals
 HSMN NewsFeed - 31 Mar 2008
ImClone Appoints Kenneth J. Zuerblis Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Mar 2008
Merck Serono Launches Cyanokit(R) in Japan
Biopharmaceuticals
 HSMN NewsFeed - 3 Mar 2008
Pro-Pharmaceuticals DAVANAT(R) Extends Median Survival 6.7 Months for End-Stage Colorectal Cancer Patients After All Other Treatments Failed
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Feb 2008
New Data Shows DAVANAT(R) Extends Survival of End-Stage Colorectal Cancer Patients More Than 6 Months
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Nov 2007
Published Data Suggest That ERBITUX(R) Enables Complete Surgical Resection of Colorectal Liver Metastases in Patients Previously Refractory to Conventional Systemic Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Nov 2007
ARIAD Expands Leadership Team with Three New Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Nov 2007
NCCN Receives Major Grant for Anti-Cancer Drug Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Nov 2007
New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Oct 2007
ImClone and Bristol-Myers Squibb Announce Joint Agreement with Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Oct 2007
Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Sep 2007
ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Sep 2007
ImClone Settles Patent Lawsuit and Gains Rights to Additional Intellectual Property
Biopharmaceuticals Oncology Litigation Licensing
 HSMN NewsFeed - 10 Sep 2007
Repligen Announces Settlement with ImClone In Erbitux(R) Lawsuit
Biopharmaceuticals Oncology Litigation Licensing
 HSMN NewsFeed - 9 Aug 2007
ImClone Systems Appoints John H. Johnson Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Jul 2007
Bristol-Myers Squibb and Imclone Systems Significantly Expand ERBITUX Clinical Development Program
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Jul 2007
Data Available From ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Jul 2007
ImClone Systems Appoints Thomas F. Deuel to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Jun 2007
FDA Accepts and Grants Priority Review of ERBITUX(R) (Cetuximab) sBLA for Overall Survival in Patients with Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Jun 2007
Extensive Clinical Data on ERBITUX(R) Presented at the 2007 ASCO Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Clinical Data Suggest Potential Versatility of ALIMTA(R) (Pemetrexed for Injection)-Based Regimens in Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 May 2007
NCCN Updates Head and Neck Cancers Guidelines
Biopharmaceuticals Devices Oncology
 HSMN NewsFeed - 9 May 2007
Poniard Pharmaceuticals Appoints Ronald A. Martell President and Chief Operating Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Apr 2007
Randomized Phase III Trial Showed ERBITUX Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Apr 2007
Data Available from ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Apr 2007
Survival Data Available From ERBITUX(R) Study in First-Line Treatment of Advanced Head and Neck Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Feb 2007
ImClone Systems Incorporated and Bristol-Myers Squibb Announce Application In Japan for Use of ERBITUX in Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 1 Feb 2007
Ivrea Pharmaceuticals Appoints Daniel S. Lynch as President and Chief Executive Officer
Biopharmaceuticals
 HSMN NewsFeed - 10 Jan 2007
ERBITUX(R) Phase III Study Meets Primary Endpoint In First-Line Treatment of Metastatic Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Nov 2006
Bristol-Myers Squibb Company Announces Promotion of Andrew Bonfield and Elliott Sigal to Executive Vice Presidents
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Nov 2006
Survival Data Available from Two Randomized ERBITUX Studies in Metastatic Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Nov 2006
Introgen Obtains Exclusive License to Therapies Combining Epidermal Growth Factor Drugs and Tumor Suppressor Genes
Biopharmaceuticals Licensing Oncology
 HSMN NewsFeed - 25 Oct 2006
Carl C. Icahn Appointed Chairman of ImClone Systems
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Oct 2006
Hana Biosciences Licenses Drug Candidate for the Prevention and Treatment of EGFR Inhibitor-Associated Skin Rash
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 13 Oct 2006
ImClone Systems Directors Urge Stockholders to Reject Carl Icahn's Efforts to Opportunistically Seize Control of the Company
Biopharmaceuticals
 HSMN NewsFeed - 9 Oct 2006
GenVec Names Mark O. Thornton, MD, MPH, PhD as Senior Vice President, Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Oct 2006
Dako Receives FDA Approval for Use of EGFR pharmDx(TM) With Vectibix(TM)
Diagnostics FDA Oncology
 HSMN NewsFeed - 19 Sep 2006
ImClone Systems Issues Statement on Court Ruling in Litigation against Yeda
Biopharmaceuticals Oncology Licensing Litigation
 HSMN NewsFeed - 20 Jul 2006
ImClone Systems and Merck KGaA Amend and Supplement ERBITUX Agreement
Biopharmaceuticals Licensing
 HSMN NewsFeed - 30 Jun 2006
Receptor BioLogix Names Thomas A. Glaze Chief Executive Officer
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 92

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 92 additional stories matching:
Erbitux
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.